Recent Company News

• 09:12 AM ET Feb 05, 2026
  

  Transcript Intelligence: Orexo Q4 Earnings Themes

• 09:12 AM ET Feb 05, 2026
  

  Transcript Intelligence: Orexo Q4 Earnings Guidance

• 09:11 AM ET Feb 05, 2026
  

  Transcript Intelligence: Orexo Q4 Earnings Q&A

• 04:38 AM ET Feb 05, 2026
  

  StreetAccount Summary - Trading higher/lower: EU mid-morning

• 01:11 AM ET Feb 05, 2026
  

  Orexo reports Q4 EPS (SEK3.33) vs year-ago (SEK5.15) (SEK 29.35, 0.00)

• 11:31 AM ET Dec 31, 2025
  

  Orexo closes transaction with Dexcel Pharma USA acquiring full rights to Zubsolv (buprenorphine/naloxone) in the US (SEK 30.10, 0.00)

• 03:03 PM ET Dec 22, 2025
  

  Orexo enters into agreement with Dexcel Pharma USA to divest US rights to Zubsolv (SEK 24.00, 0.00)

• 10:02 AM ET Oct 23, 2025
  

  Transcript Intelligence: Orexo Q3 Earnings Guidance (SEK29.95, -7.55)

• 10:00 AM ET Oct 23, 2025
  

  Transcript Intelligence: Orexo Q3 Earnings Themes (SEK29.85, -7.65)

• 09:59 AM ET Oct 23, 2025
  

  Transcript Intelligence: Orexo Q3 Earnings Q&A (SEK29.70, -7.80)